Iberogast (STW5-II, BAY98-7410)
Pre-clinicalCompletedDevelopment Stage
Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia
Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia, Irritable Bowel Syndrome, Functional Dyspepsia
Jun 4, 2022 → May 11, 2023
About Iberogast (STW5-II, BAY98-7410)
Iberogast (STW5-II, BAY98-7410) is a pre-clinical stage product being developed by Bayer for Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia. The current trial status is completed. This product is registered under clinical trial identifier NCT05389709. Target conditions include Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia, Irritable Bowel Syndrome, Functional Dyspepsia.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05389709 | Pre-clinical | Completed |
Competing Products
20 competing products in Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia